中国创新药成果将再登国际学术舞台，恒生创新药ETF（159316）助力便捷布局创新药龙头公司

Core Insights - The 2025 World Lung Cancer Conference (WCLC) will be held from September 6 to September 9 in Barcelona, Spain, where Chinese pharmaceutical companies will showcase a series of innovative drug achievements [1] - In the first seven months of this year, the amount of License out (patent authorization abroad) reached nearly $80 billion, a year-on-year increase of over 160% [1] - The adjustment of the Hang Seng Hong Kong Stock Connect Innovative Drug Index has officially taken effect, becoming the first "pure" innovative drug index tracked by an ETF, accurately reflecting the overall performance of domestic innovative pharmaceutical companies [1] Industry Trends - Chinese innovative pharmaceutical companies are increasingly engaging in international markets, with significant patent authorization transactions continuing into August [1] - Analysts suggest that the essence of Chinese innovative drugs going global is to replace part of the ecological niche of overseas biotech companies, potentially leading to new breakthroughs in the global innovative drug industry [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only ETF product tracking this index, providing investors with an efficient way to invest in leading Chinese innovative pharmaceutical companies [2]